netFormulary NHS
Sunderland Joint Formulary
NHS Sunderland Clinical Commissioning Group
South Tyneside and Sunderland NHS Foundation Trust
 Search
 Formulary Chapter 1: Gastro-intestinal system - Full Chapter
01.05.03  Expand sub section  Drugs affecting the immune response
01.05.03  Expand sub section  Cytokine inhibitors
Adalimumab
(See 10.01.03 for preparations)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
 
Link  NICE TA 187: Crohn’s disease - infliximab (review) and adalimumab (review of TA40)
Link  NICE TA 329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after failure of conventional therapy
   
Golimumab
(See 10.01.03 for preparations)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
 
Link  NICE TA 329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after failure of conventional therapy
   
Infliximab (See 10.01.03 for preparations)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
 
Link  NICE TA 163: Ulcerative colitis (acute manifestations) Infliximab
Link  NICE TA 187: Crohn’s disease - infliximab (review) and adalimumab (review of TA40)
Link  NICE TA 329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after failure of conventional therapy
   
Biosimilar Infliximab (Inflectra®)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Vial (powder for reconstitution): 100mg

 
   
Ustekinumab (Stelara)
View adult BNF View SPC online View SMC online
Formulary
Red

Concentrate for solution for infusion: 130mg

 
Link  NICE TA 456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
Link  NICE TA 633: Ustekinumab for treating moderately to severely active ulcerative colitis
   
01.05.03  Expand sub section  Vedolizumab
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to SPCs
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Drugs for hospital use or use by a specialist within specialist centre only. Initiation and monitoring of treatment should remain under the total responsibility of the appropriate hospital clinician or specialist. These drugs should only be prescribed under the direct supervision of that clinician or specialist and are not suitable for shared care arrangements. The drug should be supplied via the hospital or specialist centre for the duration of treatment.   

Amber

These are specialist drugs which must be initiated by secondary care specialist prescribers, but with the potential to transfer prescribing to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care. For these drugs, in order to ensure patient safety, some aspects of care must remain with the specialist due to their complexity e.g. monitoring of disease or drug response. Other more routine aspects can be transferred to the GP e.g. monitoring of adverse effects and supply of the medicine. The specific responsibilities of the specialist and GP are defined in the shared care agreement for each drug. Shared care agreements are still under development for some amber drugs. Until these are available, it would be expected that any shared care request from secondary care to a GP would be accompanied by written information which defines prescribing and monitoring responsibilities. The hospital specialist should also provide the GP with enough information and support to allow the safe transfer and ongoing management of prescribing into primary care.   

Green +

Drugs which should usually be initiated in secondary care, or by a specialist clinician, but can be safely maintained in primary care with very little or no monitoring required. In some cases there may be a further restriction for use outlined - these will be defined in each case.  

Green

These are defined as new and established drugs, which may be prescribed, initiated, changed or maintained on FP10 by the GP and, if appropriate, discontinued without recourse to secondary care. N.B. DRUGS NOT IDENTIFIED IN THE FORMULARY BY A RED, AMBER OR GREEN+ SYMBOL ARE CLASSIFIED AS GREEN.   

netFormulary